Global Bioimpedance Analyzers Market - 2023-2030

Global Bioimpedance Analyzers Market - 2023-2030

Global Bioimpedance Analyzers Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.

Bioimpedance analyzers is a simple, inexpensive, and noninvasive body composition measurement method. BIA is based on the electrical conductive properties of the human body. Measures of bioelectrical conductivity are proportional to total body water and the body compartments with high water concentrations such as fat-free and skeletal muscle mass. BIA assumes that the body consists of two compartments, fat and fat-free mass (FFM) (Body weight). BIA is best known as a technique for the measurement of percent body fat although it has more recently been used for estimating skeletal muscle mass too.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of lifestyle diseases

The rising prevalence of various lifestyle diseases, such as obesity, high blood pressure, and diabetes, is probably due to unhealthy lifestyles, such as sedentary work environments, eating more junk food, and increased mobility automation.

For instance, according to the World Obesity Atlas 2023, over 4 billion people may be affected by 2035, compared with over 2.6 billion in 2020. Thus, there is an increase from 38% of the world's population in 2020 to over 50% by 2035. The prevalence of obesity (BMI 230kg/m2) alone is anticipated to rise from 14% to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.

Furthermore, the global bioimpedance analyzers market is also driven by various other factors like, the rising number of government and organizational initiatives for promoting physical activity and healthcare coupled with growing responsiveness regarding the healthy lifestyle drives the bioimpedance analyzers market.

Market Dynamics: Restraint

The high cost of bioimpedance analyzers is one of the factors that hamper the market growth during the forecast period. The smaller healthcare facilities, clinics, and resource-constrained regions will be limited by the high cost of analyzers. Depending on the features, capabilities, and frequency, bioimpedance analyzers can range in pricing.

For some healthcare facilities, fitness centres, and research institutions, especially smaller or resource-constrained organizations, the cost of acquiring and maintaining these devices can be a significant barrier. The price of bioimpedance analyzers can range from USD 2,000- USD 30,000.

Segment Analysis

The global bioimpedance analyzers market is segmented based on product type, modality, application, end user and region.

The multi-frequency bioimpedance analyzers from the product type segment accounted for approximately 43.5% of the bioimpedance analyzers market share

The multi-frequency bioimpedance analyzers segment from the product type segment accounted for approximately 43.5% and is expected to be dominated during the forecast period. Multi-frequency bioelectrical impedance analysis (MFBIA) differs from the more commonly utilized single-frequency bioelectrical impedance analysis in that bioimpedance data is obtained at several different frequencies, allowing for quantification of extracellular water (ECW) at low frequencies (e.g. 1 or 5 kHz), and total body water (TBW) at higher frequencies (e.g. 100, 200, or 500 kHz).

For instance, in June 2023, Withings introduced the Body Smart Scale. Featuring Withings Precision Technology that combines multifrequency bioelectrical impedance analysis (BIA), precision weight sensors, and advanced algorithms delivering insights and health analysis, the entry-level scale provides precise weight and body composition analysis as well as advanced health measurements including heart rate, visceral fat, metabolic age and basal metabolic rate.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the various factors, such as FDA clearance, increases in obesity rates, increasing healthcare spending, a growing number of fitness centers and health clubs, and an increasing geriatric population which helps the region to have highest market share during the forecast period.

For instance, in June 2023, MEDICAL IP received US FDA 510(k) Clearance for DeepCatch, AI Software for Whole-Body Composition CT Quantification. DeepCatch is a SaMD (Software as a Medical Device) that automatically segments and analyzes anatomical structures in computed tomography (CT) scans and provides the results as a report with 3D visual and quantitative information. DeepCatch is the only FDA-cleared AI software that automatically analyzes various body components such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organs, and central nervous system through whole-body CT.

COVID-19 Impact Analysis

The COVID-19 pandemic was expected to have a significant impact on market growth. This was mainly due to the high risk of obesity during the pandemic period. For instance, according to the article published in Diabetes Obesity and Metabolism in August 2021, obesity prevalence is a significant and potentially modifiable risk factor among COVID-19 patients.

Market Segmentation

By Product Type
• Multi-Frequency Bioimpedance Analyzers
• Single Frequency Bioimpedance Analyzers
• Dual Frequency Bioimpedance Analyzers

By Modality
• Wireless Bioimpedance Analyzers
• Wired Bioimpedance Analyzers

By Application
• Segmental Body Measurement
• Whole Body Measurement

By End User
• Hospitals
• Clinics
• Wellness Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Tanita Corporation, Akern, Biodynamics Corporation, Bioparhom, Biotekna, Bodystat Ltd, Charder Electronic Co. Ltd, Evolt 360, Fook Tin Group Holding Ltd, Bodivis( Tongfang Health Technology (Beijing) Co., Ltd) among others.

Key Developments

 In April 2022, InBody, a worldwide leader in body composition technology, stated the release of its BWA 2.0 body water analyzer. This new professional-grade device expands upon the outputs measured by the InBody S10 to provide users with more detailed insights that demonstrate how variations in body composition and body water can affect well-being.

 In March 2022, Analog Devices launched a low-power, high-performance analogue front end built for wearable bioimpedance monitoring, MAX30009. This device promised clinical-grade vital sign measurement for patient assessment.

Why Purchase the Report?
• To visualize the global bioimpedance analyzers' market segmentation based on product type, modality, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of bioimpedance analyzers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bioimpedance analyzers market report would provide approximately 77 tables, 79 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies